CLRB - Cellectar Bio's lead asset shows encouraging action in early-stage study of pediatric tumors

Cellectar Biosciences ([[CLRB]] -0.9%) has announced interim results from Phase 1 study evaluating CLR 131 in relapsed or refractory brain tumors, specifically high grade gliomas, high risk neuroblastomas and select soft tissue sarcomas.Four dose levels (15, 30, 45 and 60mCi/m2 ) have been evaluated to date with all deemed safe and tolerated by the independent Data Monitoring Committee; patients are currently being evaluated at the 75mCi/m2 dose level.Activity has been noted at lower dose levels, though initially it was expected to occur at doses of 60mCi/m2 and higher.CLR 131 has been measured in tumors, confirming that systemic administration of the drug candidate crosses the blood brain barrier and 20-40% of the infused CLR 131 is delivered to the tumors.Disease control has been exhibited in heavily pretreated patients with ependymomas (cancerous tumors that grow brain or any part of the spine).The company has planned initiation of pivotal trial later in the

For further details see:

Cellectar Bio's lead asset shows encouraging action in early-stage study of pediatric tumors